ARS Pharma's Neffy® Wins Major Patent Upholds, Ensuring IP Protection Until 2039
ARS Pharmaceuticals, Inc. has received significant patent reinforcements for its nasal epinephrine product, Neffy®. The United States Patent and Trademark Office and the European Patent Office have both upheld key claims for the company's patents, ensuring Neffy®'s intellectual property protection until at least 2039.
Neffy® is a nasal spray indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater. It is designed for quick and easy administration, with patients advised to use it right away if symptoms occur. If symptoms continue or worsen, a second dose can be administered using a new Neffy® in the same nostril, starting 5 minutes after the first dose.
The company's intellectual property portfolio has proven robust, successfully overcoming two independent patent challenges in different jurisdictions. ARS Pharma's CEO, Richard Lowenthal, has expressed confidence in the company's ability to continue defending its worldwide patent estate covering intranasal epinephrine against future challenges.
With its patents upheld, ARS Pharmaceuticals can continue providing Neffy® as a crucial emergency treatment option for allergies. Patients are reminded to always carry two Neffy® nasal sprays and to inform their healthcare provider about any underlying conditions or medications they are taking.
Read also:
- Web3 gaming platform, Pixelverse, debuts on Base and Farcaster networks
- Cannabis-Focused CTV Channel Citizen Green Launches for Global Streamers
- Goodyear in 2025: Advancement in Total Mobility through the Launch of Kmax Gen-3 by Goodyear
- Boston Metal pioneers route to commercial production for eco-friendly steel method
